Gregory M. Glenn - 06 Mar 2023 Form 4 Insider Report for NOVAVAX INC (NVAX)

Reporting relationship: President, R&D
Issuer ticker: NVAX
Reported as of: 06 Mar 2023
Net transaction value: +$68,248
SEC form: 4
Accepted by SEC: 14 Mar 2023, 17:16:58 UTC
Prior SEC filing: 16 Dec 2022
Source filing: View source filing
Reporting owner signature: /s/ John A. Herrmann III, Attorney-in-Fact

Key filing fact

Gregory M. Glenn filed Form 4 for NOVAVAX INC (NVAX) on 14 Mar 2023.

Key facts

This page summarizes Gregory M. Glenn's Form 4 filing for NOVAVAX INC (NVAX).
6 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Mar 2023, 17:16.

Change

Previous filing in this sequence was filed on 16 Dec 2022.
Current net transaction value: +$68,248.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVAX transaction

Common Stock

Purchase

Transaction value: $22,454
Shares: +3,000
Change %: +35%
Price: $7.48
Shares after: 11,473
Date: 06 Mar 2023
Ownership: Direct
Footnotes: F1, F2

NVAX transaction

Common Stock

Purchase

Transaction value: $14,088
Shares: +2,000
Change %: +17%
Price: $7.04
Shares after: 13,473
Date: 07 Mar 2023
Ownership: Direct
Footnotes: F3

NVAX transaction

Common Stock

Purchase

Transaction value: $6,500
Shares: +1,000
Change %: +7.4%
Price: $6.50
Shares after: 14,473
Date: 10 Mar 2023
Ownership: Direct
Footnotes: F4

NVAX transaction

Common Stock

Options Exercise

Transaction value: $41,063
Shares: +6,298
Change %: +44%
Price: $6.52
Shares after: 20,771
Date: 10 Mar 2023
Ownership: Direct
Footnotes: F5

NVAX transaction

Common Stock

Tax liability

Transaction value: $15,857
Shares: -2,432
Change %: -12%
Price: $6.52
Shares after: 18,339
Date: 10 Mar 2023
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NVAX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -6,298
Change %: -33%
Price: $0.000000
Shares after: 12,596
Date: 10 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,298
Exercise price
Footnotes: F6, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.2658 to $7.65, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

Footnote F2

Includes 464 shares acquired on January 31, 2023 under the Company's Amended and Restated 2013 Employee Stock Purchase Plan, as amended.

Footnote F3

The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.0089 to $7.0594, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

Footnote F4

The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.45 to $6.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each price within the range set forth in this footnote.

Footnote F5

The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs").

Footnote F6

Each RSU represents a contingent right to receive one share of the Company common stock.

Footnote F7

The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date.